Article Details
Retrieved on: 2021-07-26 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
(NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here